- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Sonus gains additional European approval
The European Medicines Evaluation Agency has approved the remaining manufacturing variation in Sonus Pharmaceuticals’ European marketing authorization for EchoGen, Sonus’ ultrasound contrast agent. The EMEA approval enables Sonus to begin
The European Medicines Evaluation Agency has approved the remaining manufacturing variation in Sonus Pharmaceuticals European marketing authorization for EchoGen, Sonus ultrasound contrast agent. The EMEA approval enables Sonus to begin production of EchoGen in Europe. The Bothell, WA-based company is currently in discussions with potential marketing partners in Europe and expects to have several of these relationships in place early this year. In November, Sonus took back exclusive marketing rights to EchoGen in Europe, Latin America, Canada, the Middle East, and certain Asia Pacific countries from its previous marketing partner outside the U.S., Abbott International (SCAN 11/27/99).
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
October 1st 2024Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.
